JD Imaging

JD Imaging is a biotechnology company specializing in the discovery and development of novel molecular imaging probes for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT). Founded by Dr. Hank Kung, a pioneer in radiopharmaceutical chemistry, the company focuses on creating high-affinity tracers that target biomarkers associated with neurodegenerative diseases and oncology. Their research has led to the development of significant imaging agents, including those targeting the vesicular monoamine transporter 2 (VMAT2) and amyloid-beta plaques. JD Imaging typically operates as a research and development entity, licensing its proprietary technologies to major pharmaceutical partners for clinical advancement and commercialization. Notable assets originating from the company's research have been licensed to partners such as Avid Radiopharmaceuticals (Eli Lilly) and Cerveau Technologies.